- Home
- PENG vs VERA Comparison
PENG vs VERA Comparison
Compare PENG & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | VERA |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PENG | VERA |
|---|---|---|
| Price | $56.28 | $32.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $27.78 | ★ $81.30 |
| AVG Volume (30 Days) | 1.3M | ★ 2.2M |
| Earning Date | 04-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $1,368,794,000.00 | N/A |
| Revenue This Year | $14.55 | N/A |
| Revenue Next Year | $16.14 | $472.48 |
| P/E Ratio | $42.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.04 | $23.05 |
| 52 Week High | $89.86 | $56.05 |
Technical Indicators
Market Signals| Indicator | PENG | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 43.46 |
| Support Level | $45.12 | $30.05 |
| Resistance Level | $57.50 | $33.09 |
| Average True Range (ATR) | 2.35 | 2.15 |
| MACD | 0.87 | -0.24 |
| Stochastic Oscillator | 89.17 | 13.70 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.